<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-014-0526-8</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Research</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Specifying the target difference in the primary outcome for a randomised controlled
               trial: guidance for researchers
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Cook</span>
               <span tagx="mi">A</span>
               <span tagx="fnm">Jonathan</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="jonathan.cook@ndorms.ox.ac.uk">jonathan.cook@ndorms.ox.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hislop</span>
               <span tagx="fnm">Jenni</span>
               <span tagx="insr"></span>
               <a href="jenni.hislop@newcastle.ac.uk">jenni.hislop@newcastle.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Altman</span>
               <span tagx="mi">G</span>
               <span tagx="fnm">Douglas</span>
               <span tagx="insr"></span>
               <a href="doug.altman@csm.ox.ac.uk">doug.altman@csm.ox.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Fayers</span>
               <span tagx="fnm">Peter</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="p.fayers@abdn.ac.uk">p.fayers@abdn.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Briggs</span>
               <span tagx="mi">H</span>
               <span tagx="fnm">Andrew</span>
               <span tagx="insr"></span>
               <a href="Andrew.briggs@glasgow.ac.uk">Andrew.briggs@glasgow.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Ramsay</span>
               <span tagx="mi">R</span>
               <span tagx="fnm">Craig</span>
               <span tagx="insr"></span>
               <a href="c.r.ramsay@abdn.ac.uk">c.r.ramsay@abdn.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Norrie</span>
               <span tagx="mi">D</span>
               <span tagx="fnm">John</span>
               <span tagx="insr"></span>
               <a href="j.norrie@abdn.ac.uk">j.norrie@abdn.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Harvey</span>
               <span tagx="mi">M</span>
               <span tagx="fnm">Ian</span>
               <span tagx="insr"></span>
               <a href="Ian.harvey@uea.ac.uk">Ian.harvey@uea.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Buckley</span>
               <span tagx="fnm">Brian</span>
               <span tagx="insr"></span>
               <a href="briansbuckley@gmail.com">briansbuckley@gmail.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Fergusson</span>
               <span tagx="fnm">Dean</span>
               <span tagx="insr"></span>
               <a href="dafergusson@ohri.ca">dafergusson@ohri.ca</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Ford</span>
               <span tagx="fnm">Ian</span>
               <span tagx="insr"></span>
               <a href="ian.ford@glasgow.ac.uk">ian.ford@glasgow.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Vale</span>
               <span tagx="mi">D</span>
               <span tagx="fnm">Luke</span>
               <span tagx="insr"></span>
               <a href="luke.vale@newcastle.ac.uk">luke.vale@newcastle.ac.uk</a>
            </li>
            <li tagx="au">
               <div tagx="cnm">for the DELTA group</div>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology
                  and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Nuffield
                  Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Health Services Research Unit, University of Aberdeen, Health Sciences Building, Foresthill,
                  Aberdeen AB25 2ZD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Institute of Health and Society, Newcastle University, The Baddiley-Clark Building,
                  Richardson Road, Newcastle upon Tyne NE2 4AX, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Population Health, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen
                  AB25 2ZD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Cancer Research and Molecular, Norwegian University of Science and Technology,
                  Trondheim N-7491, Norway
               </p>
            </li>
            <li tagx="ins">
               <p>Health Economics and Health Technology Assessment, University of Glasgow, 1 Lilybank
                  Gardens, Glasgow G12 8RZ, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Health Sciences
                  Building, Aberdeen AB25 2ZD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Faculty of Medicine and Health Sciences, University of East Anglia, Elizabeth Fry
                  Building, Norwich Research Park, Norwich NR4 7TJ, UK
               </p>
            </li>
            <li tagx="ins">
               <p>National University of Ireland, University Road, Galway, Ireland</p>
            </li>
            <li tagx="ins">
               <p>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 725 Parkdale Avenue,
                  Ottawa K1Y 4E9, ON, Canada
               </p>
            </li>
            <li tagx="ins">
               <p>Robertson Centre for Biostatistics, University of Glasgow, Boyd Orr Building, University
                  Avenue, Glasgow G12 8QQ, UK
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">12</span>
         <a href="http://www.trialsjournal.com/content/16/1/12">http://www.trialsjournal.com/content/16/1/12</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-014-0526-8</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">30</span>
               <span tagx="month">6</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">19</span>
               <span tagx="month">12</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">15</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Cook et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Target difference</li>
         <li tagx="kwd">clinically important difference</li>
         <li tagx="kwd">sample size</li>
         <li tagx="kwd">randomised controlled trial</li>
         <li tagx="kwd">guidance</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Central to the design of a randomised controlled trial is the calculation of the number
                  of participants needed. This is typically achieved by specifying a target difference
                  and calculating the corresponding sample size, which provides reassurance that the
                  trial will have the required statistical power (at the planned statistical significance
                  level) to identify whether a difference of a particular magnitude exists. Beyond pure
                  statistical or scientific concerns, it is ethically imperative that an appropriate
                  number of participants should be recruited. Despite the critical role of the target
                  difference for the primary outcome in the design of randomised controlled trials,
                  its determination has received surprisingly little attention. This article provides
                  guidance on the specification of the target difference for the primary outcome in
                  a sample size calculation for a two parallel group randomised controlled trial with
                  a superiority question.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods</h3>
               </div>
               <p>This work was part of the DELTA (Difference ELicitation in TriAls) project. Draft
                  guidance was developed by the project steering and advisory groups utilising the results
                  of the systematic review and surveys. Findings were circulated and presented to members
                  of the combined group at a face-to-face meeting, along with a proposed outline of
                  the guidance document structure, containing recommendations and reporting items for
                  a trial protocol and report. The guidance and was subsequently drafted and circulated
                  for further comment before finalisation.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Results</h3>
               </div>
               <p>Guidance on specification of a target difference in the primary outcome for a two
                  group parallel randomised controlled trial was produced. Additionally, a list of reporting
                  items for protocols and trial reports was generated.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Conclusions</h3>
               </div>
               <p>Specification of the target difference for the primary outcome is a key component
                  of a randomized controlled trial sample size calculation. There is a need for better
                  justification of the target difference and reporting of its specification.
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Well-conducted randomised controlled trials (RCTs) are widely viewed as providing
         the optimal evidence on the relative performance of competing healthcare interventions
         
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. However, simply detecting any statistical difference in the effectiveness of interventions
         may not be sufficient or useful; if the interventions differ to a degree or in a manner
         that is of little consequence in patient, clinical or economic (or other meaningful)
         terms, then the interventions might be considered not to be different. If RCTs are
         to produce useful information that can help patients, clinicians and planners make
         decisions about health care, it is essential that they are designed to achieve this.
         This is typically achieved by specifying a target difference for a primary outcome
         as part of a sample size calculation, which provides reassurance that the trial will
         have the specified statistical power to identify whether a difference of a particular
         magnitude exists. Beyond purely statistical or scientific concerns, the sample size
         calculation has financial and ethical implications. Failing to recruit sufficient
         participants to be able to confidently detect a relevant difference between interventions
         may be viewed as an inefficient use of finite research resources, while recruiting
         substantially more than are needed risks exposing participants to unnecessary experimentation
         
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>.
      </p>
      <p>Given these considerations, determining an appropriate sample size is of critical
         importance. Surprisingly, little practical advice is available on specifying the target
         difference of the chosen primary outcome, which as noted above is a key component
         of the sample size calculation. A comprehensive systematic review of the literature
         identified methods for determining the target difference that are available and surveys
         have shown these methods are in use 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>. Nevertheless, uncertainty regarding the magnitude of the target difference when
         designing the trial will lead to uncertainty regarding the interpretation of the results,
         even when the trial is otherwise successfully conducted 
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>.
      </p>
      <p>This article aims to provide practical guidance primarily for researchers involved
         in determining the sample size for an RCT and, in particular, the specification of
         the target difference in the primary outcome. It is also relevant to those who are
         involved in commissioning and publishing such studies. We provide guidance on the
         choice of the primary outcome, specification of the target difference and a brief
         summary of available methods that can be used to inform its specification and reporting.
         Additionally, two sets of reporting items, one for a trial protocol and the other
         a report of the trial findings in a peer reviewed biomedical journal, are also proposed
         and examples provided. A comprehensive systematic review and discussion of the individual
         methods for specifying a target difference has been reported elsewhere 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>. The focus of this guidance is upon what might be termed the conventional, or standard,
         approach to an RCT sample size calculation: a standalone trial utilising the conventional
         statistical framework for sample size calculation and primarily for superiority trials
         (those where the difference to be detected is specified). The key issues considered
         are relevant to other RCT designs and analysis approaches though implementation may
         differ. We note that the conventional approach to sample size calculation is not without
         its limitations and alternatives have been proposed 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>, nevertheless it continues to be the most widely adopted approach 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>.
      </p>
      <p>The conventional approach to the sample size calculation for a two parallel group
         RCT is as follows:
      </p>
      <p>1. The RCT is conceived as a standalone definitive study (a study that is designed
         to provide a meaningful answer on its own);
      </p>
      <p>2. It addresses a superiority question evaluating evidence of a difference (in either
         direction);
      </p>
      <p>3. Adoption of a two parallel-group RCT design (typically 1:1 allocation);</p>
      <p>4. Application of the Neyman-Pearson framework to calculate the sample size 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. This requires specification of: the primary outcome for which the required sample
         size is to be calculated; the target difference (specification varies according to
         outcome type); statistical parameters (significance level and power) and other component(s)
         of the sample size calculation (such as standard deviation (SD)).
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Development of the guidance</h3>
         </div>
         <p>This work was part of the DELTA (Difference ELicitation in TriAls) project, a study
            on target differences commissioned by the Medical Research Council/National Institute
            for Health Research Methodology Research Panel (MRC/NIHR) in the United Kingdom. It
            comprised three interlinking components: a comprehensive systematic review of methods
            for specifying the target difference, two surveys of current practice amongst clinical
            trialists and generation of structured guidance. This article is an abridged version
            of this guidance and other components of the project which have been reported in full
            elsewhere 
            <span tagx="abbrgrp">
               <span tagx="abbr">4</span>
            </span>. DELTA was undertaken by a collaborative group in which the majority of members have
            extensive experience of the design and conduct of RCTs (both as investigators and
            as independent committee members) and have conducted methodological research related
            to RCTs (such as quality-of-life measurement, statistical methodology, reporting,
            surgical trials and economic evaluation). The draft guidance was developed by the
            project steering and advisory groups utilising the results of the systematic review
            and surveys. Findings were circulated and presented to members of the combined group
            at a face-to-face meeting, along with a proposed outline of the guidance document
            structure and a list of recommendations and reporting items for a trial protocol and
            report. Both the structure and main recommendations were agreed at this meeting. The
            guidance was subsequently drafted and circulated for further comment before finalisation.
            No ethical approval was needed for this research.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Scope of the guidance</h3>
         </div>
         <p>This guidance is based upon the conventional approach to a sample size calculation,
            though it should be applicable to most RCTs 
            <span tagx="abbrgrp">
               <span tagx="abbr">1</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">9</span>
            </span>. However, other approaches, for example trials with an explicitly Bayesian analysis
            framework, will require adaptation of the reporting items. It focuses upon guidance
            for a trial with a ‘superiority’ question; one which seeks evidence of a difference
            between intervention groups. Although this guidance is primarily aimed at researchers,
            it is also relevant for publishers, funders and commissioners of research.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Results</h2>
      </div>
      <p>Abridged guidance is given below.</p>
      <div id="">
         <div tagx="st">
            <h3>Choosing the primary outcome</h3>
         </div>
         <p>In the conventional approach to the sample size calculation for an RCT, a single outcome
            is usually chosen to be the primary measure upon which the sample size calculation
            is based (in some cases more than one primary outcome may be appropriate) 
            <span tagx="abbrgrp">
               <span tagx="abbr">2</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">10</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">13</span>
            </span>. The specification of a primary outcome performs a number of functions in terms of
            trial design, but it is clearly a pragmatic simplification to aid the design, interpretation
            and use of RCT findings. Through the corresponding sample size calculation and specification
            of the target difference, it clarifies what the study aims to identify, and the statistical
            power and precision with which this can be achieved. Stating the primary outcome in
            the study protocol also helps prevents undue over-interpretation arising from testing
            multiple outcomes and selective outcome reporting bias, whereby authors report only
            statistically significant (on possibly clinically irrelevant) outcomes or change the
            primary focus of the study to match a statistically significance finding. Additionally,
            it helps clarify the initial basis upon which to judge the study findings. This is
            particularly important in presence of a ‘negative’ result, where the result does not
            meet the criteria for statistical significance (typically 5%). In all cases, focus
            should be upon the confidence interval as well as the point estimate, where a justifiable
            target difference can guide the interpretation. However, such justification of the
            target difference is often lacking in trial reports 
            <span tagx="abbrgrp">
               <span tagx="abbr">1</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">6</span>
            </span>. Calculating (or reverse engineering) the magnitude of a difference that can be detected
            at conventional levels of statistical significance and power (typically two-sided
            5% and 80%, respectively), given a sample size which is believed to feasible, is often
            performed in practice for a selection of key outcomes before determining the primary
            outcome. Nevertheless, it is important to report the final sample size calculation,
            including the chosen primary outcome, the target difference and any justification
            of the value chosen, in as robust and transparent a fashion as possible to allow others
            to judge the basis of the calculation.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Specifying the target difference</h3>
         </div>
         <p>The specification of the target difference in an RCT sample size calculation has received
            surprisingly little discussion in the literature. For a superiority trial, it is the
            difference in the primary outcome value that the study is designed to detect reliably
            
            <span tagx="abbrgrp">
               <span tagx="abbr">2</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">10</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">13</span>
            </span>. There are two main bases for specifying the target difference: a difference considered
            to be ‘important’ (for example, by a stakeholder group such as health professionals
            or patients), and a ‘realistic difference’ based upon current evidence (for example,
            seeking the best available estimates in the literature through some form of knowledge
            synthesis).
         </p>
         <p>It has been argued that a target difference should always meet both of these criteria
            
            <span tagx="abbrgrp">
               <span tagx="abbr">14</span>
            </span>. The desire to be able to consider an (clinically) important difference can be viewed
            as a middle ground between ignoring the consequences of the treatment decision and
            a full assessment of the benefits, harms and costs of an intervention against the
            alternatives, which seeks to ensure that any harms and costs are incurred for a good
            reason. Focusing on a benefit (or harm) of the most important outcome is a natural
            and intuitive, if imperfect, way to guide a decision. A large body of literature exists
            on defining a clinically important difference, though not in the context of an RCT
            sample size calculation 
            <span tagx="abbrgrp">
               <span tagx="abbr">15</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>. The most common general approach is the minimal clinically important difference
            (MCID). This has been defined as ‘the smallest difference …. which patients perceive
            as beneficial and which would mandate, in the absence of troublesome side effects
            and excessive cost, a change in the patient’s management’, or more simply as ‘minimum
            difference that is important to a patient’ 
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>. Many variants on this basic approach exist 
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span>. In the context of specifying a target difference for a typical two parallel-group
            trial, the focus is on a difference at the group level, between two groups of different
            participants. This contrasts with the vast majority of the MCID (and related) literature,
            which focuses overwhelmingly upon within-patient change and whether an important difference
            can be said to have occurred 
            <span tagx="abbrgrp">
               <span tagx="abbr">15</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>. An alternative approach is to consider all relevant issues, including the consequences
            of decision-making, whereby a difference of any magnitude can be viewed as important
            and therefore a study’s size (and implicitly the target difference) is determined
            by reference to resource implications 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span>. Whatever definition is used, estimation of an important difference is not without
            its challenges and limitations 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>.
         </p>
         <p>The other main basis for a target difference is to specify a realistic difference;
            there is, for example, little point in setting as the target difference one that is
            so large that it cannot plausibly exist. If a systematic review of RCTs on the research
            question is available, it can be used to specify what difference is supported by current
            evidence. In essence, a realistic difference makes no claim regarding its clinical
            importance or otherwise. However, where a realistic difference is used, consideration
            of the importance of the difference is needed if the study findings are intended to
            inform clinical, patient or policy decisions. For some outcomes, the importance may
            be very clear (for example, mortality), whereas for others (especially quality of
            life and surrogate outcomes) further explanation is needed. Recruitment, study management
            and finance will naturally come into play when determining the sample size of a study.
            However, such considerations do not negate concerns about what is a realistic and/or
            important difference.
         </p>
         <p>For a superiority trial it is generally accepted that the target difference should
            be a clinically important difference 
            <span tagx="abbrgrp">
               <span tagx="abbr">2</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">10</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">12</span>
            </span> or ‘at least as large as the MCID [minimum clinically important difference]’ 
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>. The target difference in a conventional sample size calculation is not the minimum
            difference that can be statistically detected; statistical significance alone is not
            a sufficient consideration for attributing importance to a difference 
            <span tagx="abbrgrp">
               <span tagx="abbr">2</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">12</span>
            </span>.
         </p>
         <p>The target difference is specified differently depending upon the type of primary
            outcome. For a continuous outcome, this target difference on either the original or
            standardised scale is often referred to as the ‘effect size’. Strictly speaking, this
            value alone does not fully (uniquely) specify the target difference; the assumed variability
            of the outcome (standard deviation) is also needed to convert the effect size between
            the original and standardised scales. For a binary outcome, the target difference
            will be conditional on the control group event proportion. To uniquely specify the
            sample size, the target difference and the control group event proportion are needed,
            which together imply a unique pair of absolute and relative target differences. Similarly,
            survival outcomes require the control group proportion or survival distribution and
            length of follow-up period to be stated, in addition to the target difference. This
            is necessary as the sample size required is sensitive to both the absolute level and
            the relative difference. Despite this, it is not uncommon for only one or the other
            to be specifically stated in trial reports.
         </p>
         <p>Seven methods for specifying the target difference have been identified 
            <span tagx="abbrgrp">
               <span tagx="abbr">4</span>
            </span> which can be used to inform the choice of target difference: anchor, distribution,
            health economic, opinion-seeking, pilot study, review of the evidence base and standardised
            effect size (see Table 
            <span tagx="tblr">1</span> for a brief summary and elsewhere for a summary of the literature assessment of the
            use of each method 
            <span tagx="abbrgrp">
               <span tagx="abbr">5</span>
            </span>).
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 1</p>
            </div>
            <caption>
               <p>
                  <b>Methods for specifying an important and/or realistic difference</b>
                  <span tagx="abbrgrp">
                     <span tagx="abbr">5</span>
                  </span>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Name</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Description</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Difference specified</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>
                        <p>
                           <i>Anchor</i>
                        </p>
                     </td>
                     <td>
                        <p>The outcome of interest can be ‘anchored’ by using either a patient’s or health professional’s
                           judgement to define an important difference. This may be achieved by comparing a patient’s
                           health before and after treatment, and then linking this change to participants who
                           showed improvement and/or deterioration using a more familiar outcome (for which either
                           patients or health professionals more readily agree on what amount of change constitutes
                           an important difference). An outcome can be anchored to another which more is known
                           about. Contrasts between patients (such as individuals with varying severity of a
                           disease) can also be used to determine a meaningful difference.
                        </p>
                     </td>
                     <td>
                        <p>Important</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Distribution</i>
                        </p>
                     </td>
                     <td>
                        <p>Approaches that determine a value based upon distributional variation. A common approach
                           is to use a value that is larger than the inherent imprecision in the measurement
                           and therefore likely to represent a minimal level for a noticeable difference.
                        </p>
                     </td>
                     <td>
                        <p>Important</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Health economic</i>
                        </p>
                     </td>
                     <td>
                        <p>Approaches that use principles of economic evaluation. These typically include both
                           resource cost and health outcomes, and define a threshold value for the cost of a
                           unit of health effect that a decision-maker is willing to pay, to estimate the overall
                           net benefit of treatment. The net benefit can be analysed in a frequentist framework
                           or take the form of a (typically Bayesian) decision-theoretic value of information
                           analysis. Due to difficulties in implementing a value of information analysis simpler
                           heuristic frameworks, also based on the principles of economic evaluation, have been
                           proposed.
                        </p>
                     </td>
                     <td>
                        <p>Important</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Opinion-seeking</i>
                        </p>
                     </td>
                     <td>
                        <p>The target difference can be based on opinions elicited from health professionals,
                           patients or others. Possible approaches include forming a panel of experts, surveying
                           the membership of a professional or patient body or interviewing individuals. This
                           elicitation process can be explicitly framed within a trial context.
                        </p>
                     </td>
                     <td>
                        <p>Important and/or realistic</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Pilot study</i>
                        </p>
                     </td>
                     <td>
                        <p>A pilot (or preliminary) study may be carried out where there is little evidence,
                           or even experience, to guide expectations and determine an appropriate target difference
                           for the trial. In a similar manner, a phase two study could be used to inform a phase
                           three study, though this would need to take account of methodological differences
                           (such as inclusion criteria and outcomes), which should be reflected in the target
                           difference.
                        </p>
                     </td>
                     <td>
                        <p>Realistic</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Review of evidence base</i>
                        </p>
                     </td>
                     <td>
                        <p>The target difference can be derived using current evidence on the research question.
                           Ideally, this would be from a systematic review or meta-analysis of RCTs. In the absence
                           of randomised evidence, evidence from observational studies could be used in a similar
                           manner. An alternative approach is to undertake a review of studies in which an important
                           difference was determined.
                        </p>
                     </td>
                     <td>
                        <p>Important and/or realistic</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Standardised effect size</i>
                        </p>
                     </td>
                     <td>
                        <p>The magnitude of the effect on a standardised scale defines the value of the difference.
                           For a continuous outcome, the standardised difference (most commonly expressed as
                           Cohen’s d effect size) can be used. Cohen’s cutoff values of 0.2, 0.5 and 0.8 for
                           small, medium and large effects, respectively, are often used. Thus a medium effect
                           corresponds simply to a change in the outcome of 0.5 SDs. Binary or survival (time-to-event)
                           outcome metrics (such as an odds, risk or hazard ratio) can be utilised in a similar
                           manner, though no widely recognised cutoff values exist. Cohen’s cutoff values approximate
                           odds ratios of 1.44, 2.48 and 4.27, respectively. Corresponding risk ratio values
                           vary according to the control group event proportion.
                        </p>
                     </td>
                     <td>
                        <p>Important</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Reporting the sample size calculation and target difference</h3>
         </div>
         <p>The assumptions made in the sample size calculation should be clearly specified. All
            inputs should be clearly stated so that the calculation can be replicated. It is recommended
            that trial protocols clearly and fully state the sample size calculations, including
            where the approach taken differs from the conventional approach (for example, the
            adoption of a Bayesian framework instead of a frequentist approach), statistical parameters
            and the target difference, with justification for the choice of values. Due to space
            restrictions in many publications the main trial paper is likely to contain less detail.
            A minimum set of items for the main trial results paper along with full specification
            in the trial protocol is recommended below in Table 
            <span tagx="tblr">2</span>. These are more extensive lists of reporting items building upon the Consolidated
            Standards for Reporting Trials (CONSORT) including the 2010 version) and Standard
            Protocol Items: Recommendations for Interventional Trials (SPIRIT) statements, which
            provide guidance on reporting the sample size calculation, but not explicitly how
            to report the target difference and its justification 
            <span tagx="abbrgrp">
               <span tagx="abbr">25</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">27</span>
            </span> Examples for the three most common outcome types are provided in Table 
            <span tagx="tblr">3</span>.
            
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 2</p>
            </div>
            <caption>
               <p>
                  <b>Reporting items for the protocol and report of a two parallel group superiority trial</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Item no.</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Item description</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Protocol</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Report</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>
                        <p>
                           <i>1</i>
                        </p>
                     </td>
                     <td>
                        <p>State any divergence from the conventional approach.</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>2</i>
                        </p>
                     </td>
                     <td>
                        <p>State the primary outcome (and any other outcome which the study sample size calculation
                           is based upon), or state why there is not one.
                        </p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>3</i>
                        </p>
                     </td>
                     <td>
                        <p>Reference the formula and/or simulation approach if the standard binary, continuous
                           or survival outcome formulas are not used 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">2</span>
                           </span>,
                           <span tagx="abbrgrp">
                              <span tagx="abbr">11</span>
                           </span>. The primary analysis should be stated in the statistical analysis section.
                        </p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>4</i>
                        </p>
                     </td>
                     <td>
                        <p>State the values used for statistical parameters (such as significance level and power).</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>5</i>
                        </p>
                     </td>
                     <td>
                        <p>State the underlying basis for determining the target difference:</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>a. an important difference as judged by a stakeholder,</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>b. a realistic difference based upon current knowledge or</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>c. both an important and realistic difference.</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>6</i>
                        </p>
                     </td>
                     <td>
                        <p>Express the target difference according to the outcome type:</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>a. Binary: state the target difference as an absolute and/or relative effect, along
                           with the intervention and control group proportions. If both an absolute and a relative
                           difference are provided, clarify if either takes primacy in terms of the sample size
                           calculation.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>b. Continuous: state the target mean difference on the natural scale, the common SD
                           and standardised effect size (mean difference/SD). It is preferable to also provide
                           the anticipated control group mean even though it is not required for the sample size
                           calculation.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>c. Time-to-event (survival): state the target difference as an absolute and/or relative
                           difference, provide the control group event proportion, along with the intervention
                           and control group survival distributions. Additionally, the planned length of follow-up
                           should be stated along with the assumed accrual pattern. If both an absolute and a
                           relative difference are provided, clarify if either takes primacy in terms of the
                           sample size calculation.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>7</i>
                        </p>
                     </td>
                     <td>
                        <p>Explain the choice of target difference: specify and reference any formal method used
                           or relevant previous research.
                        </p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>8</i>
                        </p>
                     </td>
                     <td>
                        <p>State the sample size based upon the assumptions specified above (for a time-to-event
                           outcome, the number of events required should also be stated). If any factors are
                           incorporated which alter the required sample size (such as allowance for loss-to-follow-up)
                           they should also be specified along with the final sample size.
                        </p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>9</i>
                        </p>
                     </td>
                     <td>
                        <p>Reference the trial protocol</p>
                     </td>
                     <td></td>
                     <td>
                        <p>√</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
         <table>
            <div tagx="title">
               <p>Table 3</p>
            </div>
            <caption>
               <p>
                  <b>Reworked example RCT protocol sample size calculation sections</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Primary outcome type</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Example text</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>
                        <p>
                           <i>Binary</i>
                        </p>
                     </td>
                     <td>
                        <p>Men After Prostate Surgery (MAPS) radical prostatectomy trial 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">28</span>
                           </span>: The primary outcome is continence. The sample size was based upon a target difference
                           of 15% absolute difference (85 versus 70%). This magnitude of a target difference
                           was determined as both a realistic and important difference from discussion between
                           clinicians and the project management group, and inspection of the proportion of urinary
                           incontinence in the trials included in the Cochrane systematic review 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">29</span>
                           </span>. The control group proportion is also based upon the observed proportion in the RCTs
                           in this review. Setting the statistical significance to the two-sided 5% level and
                           seeking 90% power, 174 participants per group are required; 348 in total.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Continuous</i>
                        </p>
                     </td>
                     <td>
                        <p>Full-thickness macular hole and Internal Limiting Membrane peeling Study (FILMS) 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">7</span>
                           </span>: The primary outcome is ETDRS (Early Treatment Diabetic Retinopathy Study) distance
                           visual acuity. A target difference of a mean difference of five letters, with a common
                           standard deviation (SD) of 12, was assumed as five letters is equivalent to one line
                           on a visual acuity chart and is viewed as an important difference by patients and
                           clinicians. The SD value was based upon two previous studies; one RCT and one observational
                           comparative study 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">30</span>
                           </span>,
                           <span tagx="abbrgrp">
                              <span tagx="abbr">31</span>
                           </span>. This target difference is equivalent to a standardised effect size of 0.42. Setting
                           the statistical significance to the two-sided 5% level and seeking 90% power, 123
                           participants per group are required; 246 in total.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <i>Time to event</i>
                        </p>
                     </td>
                     <td>
                        <p>Arterial Revascularisation Trial (ART) 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">32</span>
                           </span>: The primary outcome is all-cause mortality. The sample size was based upon a target
                           difference of 5% in 10-year mortality with a control group mortality of 25%. Both
                           the difference and control group mortality proportions are realistic based upon a
                           systematic review of observational (cohort) studies 
                           <span tagx="abbrgrp">
                              <span tagx="abbr">33</span>
                           </span>. Setting the statistical significance to the two-sided 5% level and seeking 90% power,
                           1464 participants per group are required; 2,928 participants (651 events) in total.
                           Participants will be followed for 10 years.
                        </p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>The RCT is widely considered to be the best method for comparing the effectiveness
         of health interventions 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. Determining the target difference is a key element of an RCT design. Improved standards
         in both RCT sample size calculations and reporting of these calculations would aid
         health professionals, patients, researchers and funders in judging the strength of
         the available evidence and would ensure better use of scarce resources. While no single
         method provides a perfect solution to a difficult question, we have provided practical
         guidance for researchers on sample size calculation with reference to specifying the
         target difference and how this should be reported in trial protocols and reports.
         To our knowledge, no alternative guidance exists. Although our examples and framing
         are from a medical context, the issues are relevant to social care, animal and other
         non-medical research as well. Further research into the implementation, practicality
         and consequence of using alternative methods for specifying the target difference
         (such as health economic and opinion-seeking), and exploration of the justification
         of some methods (such as the standardised effect size method, where the magnitude
         of the effect is used to infer the important of a difference) is needed.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Conclusions</h2>
      </div>
      <p>Specification of the target difference for the primary outcome is a key component
         of an RCT sample size calculation. There is a need for better justification of the
         target difference and for corresponding reporting of its specification. Raising the
         standard of RCT sample size calculations would aid health professionals, patients,
         researchers and funders in judging the strength of the evidence and would ensure better
         use of scarce resources.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>ART: Arterial Revascularisation Trial</p>
      <p>CONSORT: Consolidated Standards of Reporting Trials</p>
      <p>DELTA: Difference Elicitation in TriAls</p>
      <p>ETDRS: Early Treatment Diabetic Retinopathy Study</p>
      <p>FILMS: Full-thickness macular hole and Internal Limiting Membrane peeling Study</p>
      <p>MAPS: Men After Prostate Surgery</p>
      <p>MCID: Minimal(ly) clinical(ly) important difference</p>
      <p>MRC: Medical Research Council</p>
      <p>NIHR: National Institute for Health Research</p>
      <p>RCT: Randomised controlled trial</p>
      <p>SD: standard deviation</p>
      <p>SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>All authors have completed the Unified Competing Interest form (available on request
         from the corresponding author) and declare that all authors have no financial relationships
         that might have an interest in the submitted work.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>JAC had the original idea and wrote the first draft of this paper. JH, DGA, PMF, AHB,
         CRR, JDN, IMH, BB, DF, IF and LDV contributed to the development of the guidance and
         commented on the draft manuscript. All authors read and approved the final version.
      </p>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>The authors would like to acknowledge the other members of the DELTA group (Kirsten
               Harrild, Temitope E Adewuyi and Cynthia Fraser) and the advisory group who were involved
               in the wider project (Adrian Grant and Marion Campbell). Funding was received from
               the MRC/NIHR Methodology Research Panel which is jointly funded by the MRC (reference
               number: G0902147) and Health Technology Assessment (HTA) (project number: 06/98/01).
               Jonathan Cook held MRC training (reference number: G0601938) and methodology (reference
               number: G1002292) fellowships while this research was undertaken. The Health Services
               Research Unit, Institute of Applied Health Sciences (University of Aberdeen), is core-funded
               by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates.
               The funders had no involvement in study design, collection, analysis and interpretation
               of data, reporting or the decision to publish.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Reporting of sample size calculation in randomised controlled trials: review</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Charles</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Giraudeau</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dechartres</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baron</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ravaud</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">338</span>
            <span tagx="fpage">b1732</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.b1732</span>
                  <span tagx="pubid">19435763</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Julious</span>
                  <span tagx="fnm">S</span>
               </li>
            </ul>
            <span tagx="source">Sample Sizes for Clinical Trials</span>
            <div tagx="publisher">Chapman and Hall/CRC Press, Boca Raton, FL</div>
            <span tagx="pubdate">2010</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>What influences recruitment to randomised controlled trials? A review of trials funded
                  by two UK funding agencies
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">McDonald</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Knight</span>
                  <span tagx="fnm">RC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Campbell</span>
                  <span tagx="fnm">MK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Entwistle</span>
                  <span tagx="fnm">VA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grant</span>
                  <span tagx="fnm">AM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Elbourne</span>
                  <span tagx="fnm">DR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Francis</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Garcia</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Roberts</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Snowdon</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">Trials</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1745-6215-7-9</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Assessing methods to specify the targeted difference for a randomised controlled trial
                  – DELTA (Difference ELicitation in TriAls) review
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hislop</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Adewuyi</span>
                  <span tagx="fnm">TE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Harrild</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ramsay</span>
                  <span tagx="fnm">CR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fraser</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Buckley</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fayers</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Harvey</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Briggs</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Norrie</span>
                  <span tagx="fnm">JD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fergusson</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ford</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vale</span>
                  <span tagx="fnm">LD</span>
               </li>
            </ul>
            <span tagx="source">Health Technol Assess</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">18</span>
            <span tagx="fpage">28</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.3310/hta18280</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methods for specifying the target difference in a randomised controlled trial: the
                  Difference ELicitation in TriAls (DELTA) systematic review
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hislop</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Adewuyi</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vale</span>
                  <span tagx="fnm">LD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Harrild</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fraser</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gurung</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Briggs</span>
                  <span tagx="fnm">AH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fayers</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ramsay</span>
                  <span tagx="fnm">CR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Norrie</span>
                  <span tagx="fnm">JD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Harvey</span>
                  <span tagx="fnm">IM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Buckley</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">JA</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>for the DELTA group</p>
               </li>
            </ul>
            <span tagx="source">PLoS Med</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">e1001645</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pmed.1001645</span>
                  <span tagx="pubid">24824338</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Surgery with disc prosthesis versus rehabilitation in patients with low back pain
                  and degenerative disc: two year follow-up of randomised study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hellum</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Johnsen</span>
                  <span tagx="fnm">LG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Storheim</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nygaard</span>
                  <span tagx="fnm">OP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brox</span>
                  <span tagx="fnm">JI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rossvoll</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ro</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sandvik</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grundnes</span>
                  <span tagx="fnm">O</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>Norwegian Spine Study Group</p>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">342</span>
            <span tagx="fpage">d2786</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.d2786</span>
                  <span tagx="pubid">21596740</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Internal limiting membrane peeling versus no peeling for idiopathic full-thickness
                  macular hole: a pragmatic randomized controlled trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lois</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Burr</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Norrie</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vale</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McDonald</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boachie</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ternent</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McPherson</span>
                  <span tagx="fnm">G</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>for the Full-thickness macular hole and Internal Limiting Membrane peeling Study (FILMS)
                     Group
                  </p>
               </li>
            </ul>
            <span tagx="source">Invest Ophthalmol Vis Sci</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">52</span>
            <span tagx="fpage">1586</span>
            <span tagx="lpage">1592</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1167/iovs.10-6287</span>
                  <span tagx="pubid">21051731</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Current sample size conventions: flaws, harms, and alternatives</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bacchetti</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">BMC Med</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">8</span>
            <span tagx="fpage">17</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1741-7015-8-17</span>
                  <span tagx="pubid">20307281</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Sample size determinations in original research protocols for randomised clinical
                  trials submitted to UK research ethics committees: review
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Clark</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Berger</span>
                  <span tagx="fnm">U</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mansmann</span>
                  <span tagx="fnm">U</span>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">346</span>
            <span tagx="fpage">f1135</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.f1135</span>
                  <span tagx="pubid">23518273</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Friedman</span>
                  <span tagx="fnm">LM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Furberg</span>
                  <span tagx="fnm">CD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">DeMets</span>
                  <span tagx="fnm">DL</span>
               </li>
            </ul>
            <span tagx="source">Fundamentals of Clinical Trials</span>
            <div tagx="publisher">Springer, New York</div>
            <span tagx="pubdate">2010</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Matthews</span>
                  <span tagx="fnm">JN</span>
               </li>
            </ul>
            <span tagx="source">Introduction to Randomized Controlled Clinical Trials</span>
            <div tagx="publisher">Taylor &amp; Francis, London</div>
            <span tagx="pubdate">2006</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Peace</span>
                  <span tagx="fnm">KE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chen</span>
                  <span tagx="fnm">DG</span>
               </li>
            </ul>
            <span tagx="source">Clinical Trial Methodology</span>
            <div tagx="publisher">Chapman &amp; Hall, London</div>
            <span tagx="pubdate">2010</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Pocock</span>
                  <span tagx="fnm">SJ</span>
               </li>
            </ul>
            <span tagx="source">Clinical Trials: A Practical Approach</span>
            <div tagx="publisher">Wiley &amp; Co, Chichester</div>
            <span tagx="pubdate">1983</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Sample size calculation for clinical trials: the impact of clinician beliefs</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Fayers</span>
                  <span tagx="fnm">PM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cuschieri</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fielding</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Craven</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Uscinska</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Freedman</span>
                  <span tagx="fnm">L</span>
               </li>
            </ul>
            <span tagx="source">Br J Cancer</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">82</span>
            <span tagx="fpage">213</span>
            <span tagx="lpage">219</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1054/bjoc.1999.0902</span>
                  <span tagx="pubid">10638992</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Understanding the minimum clinically important difference: a review of concepts and
                  methods
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Copay</span>
                  <span tagx="fnm">AG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Subach</span>
                  <span tagx="fnm">BR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Glassman</span>
                  <span tagx="fnm">SD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Polly</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schuler</span>
                  <span tagx="fnm">TC</span>
               </li>
            </ul>
            <span tagx="source">Spine J</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">541</span>
            <span tagx="lpage">546</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.spinee.2007.01.008</span>
                  <span tagx="pubid">17448732</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Minimal clinically important differences: Review of methods</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wells</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beaton</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shea</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boers</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Simon</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Strand</span>
                  <span tagx="fnm">V</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brooks</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tugwell</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">28</span>
            <span tagx="fpage">406</span>
            <span tagx="lpage">412</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">11246688</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Many faces of the minimal clinically important difference (MICD): A literature review
                  and directions for future research
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Beaton</span>
                  <span tagx="fnm">DE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boers</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wells</span>
                  <span tagx="fnm">GA</span>
               </li>
            </ul>
            <span tagx="source">Curr Opin Rheumatol</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">14</span>
            <span tagx="fpage">109</span>
            <span tagx="lpage">114</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/00002281-200203000-00006</span>
                  <span tagx="pubid">11845014</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The concept of clinically meaningful difference in health-related quality-of-life
                  research. How meaningful is it?
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hays</span>
                  <span tagx="fnm">RD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Woolley</span>
                  <span tagx="fnm">JM</span>
               </li>
            </ul>
            <span tagx="source">Pharmacoeconomics</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">18</span>
            <span tagx="fpage">419</span>
            <span tagx="lpage">423</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.2165/00019053-200018050-00001</span>
                  <span tagx="pubid">11151395</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Sufficiently important difference: expanding the framework of clinical significance</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Barrett</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brown</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mundt</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brown</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Med Decis Making</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">25</span>
            <span tagx="fpage">250</span>
            <span tagx="lpage">261</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1177/0272989X05276863</span>
                  <span tagx="pubid">15951453</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Optimal clinical trial design using value of information methods with imperfect implementation</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Willan</span>
                  <span tagx="fnm">AR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Eckermann</span>
                  <span tagx="fnm">S</span>
               </li>
            </ul>
            <span tagx="source">Health Econ</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">19</span>
            <span tagx="fpage">549</span>
            <span tagx="lpage">561</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">19399753</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A Bayesian cost-benefit approach to the determination of sample size in clinical trials</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kikuchi</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pezeshk</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gittins</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Stat Med</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">27</span>
            <span tagx="fpage">68</span>
            <span tagx="lpage">82</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/sim.2965</span>
                  <span tagx="pubid">17566967</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Arbitrary metrics in psychology</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Blanton</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jaccard</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Am Psychol</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">61</span>
            <span tagx="fpage">27</span>
            <span tagx="lpage">41</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1037/0003-066X.61.1.27</span>
                  <span tagx="pubid">16435974</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The rise and fall of the “minimum clinically important difference”</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Carragee</span>
                  <span tagx="fnm">EJ</span>
               </li>
            </ul>
            <span tagx="source">Spine J</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">283</span>
            <span tagx="lpage">284</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.spinee.2010.02.013</span>
                  <span tagx="pubid">20362245</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Statistical significance versus clinical importance: trials on exercise therapy for
                  chronic low back pain as example
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Van</span>
                  <span tagx="fnm">TM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Malmivaara</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hayden</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koes</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">Spine</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">32</span>
            <span tagx="fpage">1785</span>
            <span tagx="lpage">1790</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/BRS.0b013e3180b9ef49</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The revised CONSORT statement for reporting randomized trials: explanation and elaboration</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schulz</span>
                  <span tagx="fnm">KF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moher</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Egger</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Davidoff</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Elbourne</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gøtzsche</span>
                  <span tagx="fnm">PC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lang</span>
                  <span tagx="fnm">T</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>CONSORT group</p>
               </li>
            </ul>
            <span tagx="source">Ann Intern Med</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">134</span>
            <span tagx="fpage">663</span>
            <span tagx="lpage">694</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7326/0003-4819-134-8-200104170-00012</span>
                  <span tagx="pubid">11304107</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised
                  trials
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Schulz</span>
                  <span tagx="fnm">KF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moher</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>CONSORT Group</p>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">340</span>
            <span tagx="fpage">c332</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.c332</span>
                  <span tagx="pubid">20332509</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>SPIRIT 2013 statement: defining standard protocol items for clinical trials</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chan</span>
                  <span tagx="fnm">AW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tetzlaff</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Laupacis</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gotzsche</span>
                  <span tagx="fnm">PC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Krleža-Jerić</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hróbjartsson</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mann</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dickersin</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Berlin</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Doré</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Parulekar</span>
                  <span tagx="fnm">WR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Summerskill</span>
                  <span tagx="fnm">WS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Groves</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schulz</span>
                  <span tagx="fnm">KF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sox</span>
                  <span tagx="fnm">HC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rockhold</span>
                  <span tagx="fnm">FW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rennie</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moher</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">Ann Intern Med</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">158</span>
            <span tagx="fpage">200</span>
            <span tagx="lpage">207</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7326/0003-4819-158-3-201302050-00583</span>
                  <span tagx="pubid">23295957</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following
                  radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel
                  randomised controlled trials
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Glazener</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boachie</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Buckley</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cochran</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dorey</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grant</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hagen</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kilonzo</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McDonald</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McPherson</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moore</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Norrie</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ramsay</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vale</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">N'Dow</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">378</span>
            <span tagx="fpage">328</span>
            <span tagx="lpage">337</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(11)60751-4</span>
                  <span tagx="pubid">21741700</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Conservative management for postprostatectomy urinary incontinence</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hunter</span>
                  <span tagx="fnm">KF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moore</span>
                  <span tagx="fnm">KN</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Glazener</span>
                  <span tagx="fnm">CM</span>
               </li>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">2</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">17443512</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Macular hole surgery with and without internal limiting membrane peeling</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Brooks</span>
                  <span tagx="fnm">HL</span>
                  <div tagx="suf">Jr</div>
               </li>
            </ul>
            <span tagx="source">Ophthalmology</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">107</span>
            <span tagx="fpage">1939</span>
            <span tagx="lpage">1948</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0161-6420(00)00331-6</span>
                  <span tagx="pubid">11013203</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effect of autologous platelet concentrate in surgery for idiopathic macular hole:
                  results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole
                  Surgery Group
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Paques</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chastang</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mathis</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sahel</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Massin</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dosquet</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Korobelnik</span>
                  <span tagx="fnm">JF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Le Gargasson</span>
                  <span tagx="fnm">JF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gaudric</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Ophthalmology</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">106</span>
            <span tagx="fpage">932</span>
            <span tagx="lpage">938</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0161-6420(99)00512-6</span>
                  <span tagx="pubid">10328392</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare
                  survival following bilateral versus single internal mammary grafting in coronary revascularisation
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Taggart</span>
                  <span tagx="fnm">DP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lees</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gray</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Flather</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Channon</span>
                  <span tagx="fnm">K</span>
               </li>
            </ul>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>and the ART Investigator</p>
               </li>
            </ul>
            <span tagx="source">Trials</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1745-6215-7-7</span>
                  <span tagx="pubid">16573820</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effect of arterial revascularisation on survival: a systematic review of studies comparing
                  bilateral and single internal mammary arteries
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Taggart</span>
                  <span tagx="fnm">DP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">D’Amico</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">358</span>
            <span tagx="fpage">870</span>
            <span tagx="lpage">875</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(01)06069-X</span>
                  <span tagx="pubid">11567701</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>